Canada Insulin Market Size & Outlook, 2023-2030

The insulin market in Canada is expected to reach a projected revenue of US$ 878.3 million by 2030. A compound annual growth rate of 1.4% is expected of Canada insulin market from 2024 to 2030.
Revenue, 2023 (US$M)
$797.6
Forecast, 2030 (US$M)
$878.3
CAGR, 2024 - 2030
1.4%
Report Coverage
Canada

Canada insulin market highlights

  • The Canada insulin market generated a revenue of USD 797.6 million in 2023 and is expected to reach USD 878.3 million by 2030.
  • The Canada market is expected to grow at a CAGR of 1.4% from 2024 to 2030.
  • In terms of segment, insulin analog was the largest revenue generating type in 2023.
  • Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.

Insulin market data book summary

Market revenue in 2023USD 797.6 million
Market revenue in 2030USD 878.3 million
Growth rate1.4% (CAGR from 2023 to 2030)
Largest segmentInsulin analog
Fastest growing segmentInsulin Analog
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationInsulin Analog, Human Insulin
Key market players worldwideNovo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar

Other key industry trends

  • In terms of revenue, Canada accounted for 4.0% of the global insulin market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. insulin market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 878.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Insulin Market Companies

Name Profile # Employees HQ Website

Canada insulin market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.


Insulin analog was the largest segment with a revenue share of 86.51% in 2023. Horizon Databook has segmented the Canada insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.


  • Canada Insulin Type Outlook (Revenue, USD Million, 2018-2030)
    • Insulin Analog
    • Human Insulin
  • Canada Insulin Application Outlook (Revenue, USD Million, 2018-2030)
    • Type 1 Diabetes
    • Type 2 Diabetes
  • Canada Insulin Product Outlook (Revenue, USD Million, 2018-2030)
    • Rapid-Acting Insulin
    • Long-Acting Insulin
    • Combination Insulin
    • Biosimilar
    • Other Product Types
  • Canada Insulin Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacies
    • Retail & Specialty Pharmacies
    • Other Distribution Channels

Reasons to subscribe to Canada insulin market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Canada insulin market databook

  • Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada insulin market , including forecasts for subscribers. This country databook contains high-level insights into Canada insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Canada insulin market size, by type, 2018-2030 (US$M)

Canada Insulin Market Outlook Share, 2023 & 2030 (US$M)

Canada insulin market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more